The stock of Mylan NV (NASDAQ:MYL) is a huge mover today! About 11.24 million shares traded hands or 51.89% up from the average. Mylan NV (NASDAQ:MYL) has declined 22.11% since March 7, 2016 and is downtrending. It has underperformed by 29.70% the S&P500.
The move comes after 5 months positive chart setup for the $20.94 billion company. It was reported on Oct, 10 by Barchart.com. We have $52.07 PT which if reached, will make NASDAQ:MYL worth $6.91 billion more.
Analysts await Mylan NV (NASDAQ:MYL) to report earnings on November, 4. They expect $1.60 EPS, up 11.89% or $0.17 from last year’s $1.43 per share. MYL’s profit will be $855.79 million for 6.12 P/E if the $1.60 EPS becomes a reality. After $1.16 actual EPS reported by Mylan NV for the previous quarter, Wall Street now forecasts 37.93% EPS growth.
Mylan NV (NASDAQ:MYL) Ratings Coverage
Out of 13 analysts covering Mylan Inc. (NASDAQ:MYL), 7 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 54% are positive. Mylan Inc. has been the topic of 24 analyst reports since July 27, 2015 according to StockzIntelligence Inc. As per Monday, September 21, the company rating was initiated by Barclays Capital. The firm has “Buy” rating given on Friday, November 13 by Citigroup. The firm has “Buy” rating given on Wednesday, August 19 by BTIG Research. As per Wednesday, May 4, the company rating was maintained by Leerink Swann. The firm has “Market Perform” rating by Wells Fargo given on Friday, February 19. The rating was maintained by RBC Capital Markets on Tuesday, September 6 with “Sector Perform”. Morgan Stanley reinitiated the stock with “Equal-Weight” rating in Thursday, December 3 report. The stock has “Outperform” rating given by Leerink Swann on Saturday, August 29. The stock of Mylan NV (NASDAQ:MYL) earned “Outperform” rating by Leerink Swann on Monday, August 15. Cowen & Co downgraded Mylan NV (NASDAQ:MYL) on Monday, July 27 to “Market Perform” rating.
According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 0.45 in Q2 2016. Its down 0.05, from 0.5 in 2016Q1. The ratio dived, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. 1 funds bought stakes while 4 increased positions. They now own 533,685 shares or 37.96% less from 860,251 shares in 2016Q1.
Westport Res Management accumulated 0.37% or 26,765 shares. Princeton Portfolio Strategies Group Inc Llc last reported 1.89% of its portfolio in the stock. Vantage Inv Advsrs Limited Liability owns 712 shares or 0.01% of their US portfolio. Jacobs & Ca, a California-based fund reported 7,305 shares. The Florida-based Eagle Asset Management has invested 0.02% in Mylan NV (NASDAQ:MYL). Covington Capital, a California-based fund reported 39,339 shares. Moreover, Icon Advisers Comm has 0.1% invested in Mylan NV (NASDAQ:MYL) for 35,000 shares. American Research Mngmt Com has 1,600 shares for 0.03% of their US portfolio. Gemmer Asset Mgmt Lc holds 0% or 21 shares in its portfolio. Novare Cap Limited Liability Company last reported 79,851 shares in the company. Gulf Int Commercial Bank (Uk) accumulated 123,183 shares or 0.09% of the stock. Ntv Asset Ltd Liability has 0.26% invested in the company for 15,990 shares.
More notable recent Mylan NV (NASDAQ:MYL) news were published by: Investorplace.com which released: “3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and …” on October 10, 2016, also Reuters.com with their article: “Mylan to pay $465 million over EpiPen Medicaid rebate dispute” published on October 07, 2016, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 06, 2016. More interesting news about Mylan NV (NASDAQ:MYL) were released by: Profitconfidential.com and their article: “Mylan NV: MYL Stock Chart Has Ominous Implications” published on October 04, 2016 as well as Schaeffersresearch.com‘s news article titled: “Buzz Stocks: Twitter Inc, Mylan NV, and Merck & Co., Inc.” with publication date: October 10, 2016.
MYL Company Profile
Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.